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Programmed death ligand 1 (PD-L1) is expressed on a number of immune and cancer cells,
where it can downregulate antitumor immune responses. Its expression has been linked to
metabolic changes in these cells. Here we develop a radiolabeled camelid single-domain
antibody (anti-PD-L1 VHH) to track PD-L1 expression by immuno-positron emission tomo-
graphy (PET). PET-CT imaging shows a robust and speciﬁc PD-L1 signal in brown adipose
tissue (BAT). We conﬁrm expression of PD-L1 on brown adipocytes and demonstrate that
signal intensity does not change in response to cold exposure or β-adrenergic activation.
This is the ﬁrst robust method of visualizing murine brown fat independent of its activation
state.
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Monoclonal antibodies that target the immunologicalcheckpoints PD-1 (programmed cell death protein 1;CD279) and PD-L1 (programmed death ligand 1;
CD274) have proven successful in the treatment of multiple
cancers, notably metastatic melanoma, where PD-1 blockade is
now part of the standard of care1–4. PD-L1 shows broad but low
expression on myeloid cells and in other tissue types, but in
response to interferon-γ (IFNγ), its expression increases. A wide
range of human and murine malignancies express PD-L1 con-
stitutively or inducibly5–7. Despite robust expression in the tumor
microenvironment and in the setting of chronic viral infections,
expression of PD-L1 in naive mice is low, and mice lacking PD-
L1 show only modest immunologic aberrations8.
Despite the impressive gains in immunotherapy for cancer,
heterogeneous outcomes necessitate new methods to monitor and
predict patient responses. A method that comprehensively
monitors PD-L1 expression could be of diagnostic value, and may
help resolve lingering questions about the role of PD-L1 expres-
sion in checkpoint blockade responses9–11. To this end, we
developed camelid single-domain antibodies, also known as
VHHs, against immune surface proteins to monitor inﬂammation
in the tumor microenvironment by immuno-positron emission
tomography-computed tomography (PET-CT)12. We sought to
extend our method to imaging lower abundance immune
receptors, and chose PD-L1 as both a clinically relevant target and
a protein with weak expression in naive animals4, 9–11. In the
course of these experiments, we identiﬁed brown adipocytes as
the major source of surface-disposed PD-L1 expression in naive
mice.
Activated brown adipose tissue (BAT) increases body tem-
perature and energy expenditure in infants and hibernating ani-
mals13. In brown adipocytes, the generation of ATP from the
breakdown of glucose and fatty acids is interrupted by the
expression of Ucp1 (Uncoupling protein 1) in the inner mito-
chondrial membrane, where it dissipates the proton gradient
established by the electron transport chain with concomitant
release of heat14. Ucp1 expression is up-regulated by cold expo-
sure and subsequent signaling through β-adrenoreceptors14, 15
While it was previously believed that adult mammals lack BAT,
imaging with the glucose analog 2-18F-ﬂuorodeoxyglucose (18F-
FDG) by positron emission tomography (PET) shows that adult
humans have small residual BAT stores16–18. BAT is typically
identiﬁed with functional markers that monitor BAT activity,
using traceable metabolites like 18F-FDG, but there are currently
no means to visualize non-activated BAT, although tissue can be
identiﬁed by histological means in the absence of 18F-FDG
uptake19. Unlike metabolite-based imaging reagents, the ability to
visualize PD-L1 expression on brown adipocytes is independent
of temperature exposure or β-adrenergic signaling, and shows
robust staining of BAT deposits not visible by other non-invasive
methods. Our studies thus provide a new tool to screen for
therapeutic interventions of BAT function in metabolic disorders.
Imaging of BAT will be essential if we are to harness its biology
for the treatment of obesity, type 2 diabetes, and other metabolic
disorders20.
Results
Generation of a single-domain antibody against mouse PD-L1.
We immunized an alpaca with the puriﬁed ectodomain of mouse
PD-L1, leading to the isolation by phage display of two single-
domain antibodies (VHHs), termed B3 and A12, both of which
bind speciﬁcally to PD-L1 with overlapping binding epitopes and
estimated afﬁnities in the low nM range (Supplementary
Fig. 1a–f)21–23. We mapped the epitope recognized by B3 using a
panel of HEK 293 derivatives transfected with constructs
specifying single amino acid substitutions in PD-L1. When we
mapped the mutations that abolish binding of B3 to PD-L1 onto
the known structure of PD-L1, they clustered in and around the
site known to interact with its ligand, programmed cell death
protein 1 (PD-1) (Supplementary Fig. 2A; Supplementary
Table 1), suggesting that B3 could block interactions between PD-
L1 and PD-1. In vitro competition experiments conﬁrmed that B3
competes for binding with both PD-1 and the alternative ligand
B7-1 (CD80) for PD-L1 binding, with a potency similar to that of
the commercial monoclonal antibody (Supplementary Fig. S2B)5.
PET/CT with 18F- B3 reveals PD-L1 on brown adipose tissue.
PET-CT imaging with 18F-labeled B3 showed a robust signal two
hours after injection in interscapular brown adipose tissue (BAT)
in wild-type (WT), but not PD-L1 knockout (KO), mice (Fig. 1a,
b; Supplementary Fig. 1a). Labeling of B3 with 18F or 64Cu pro-
duced equivalent results in terms of tissue distribution, with non-
speciﬁc staining in the lumen of the gut and in kidney, a trait
common to all VHHs used in PET imaging (Supplementary
Fig. 3b). The B3 VHH binds PD-L1 in vivo, and thus BAT
expresses PD-L1. The presence of PD-L1 is evident not only in
the intrascapular region, but covers the distribution of all brown
fat in the thorax, with small deposits below the scapulae and in
elongated structures parallel to the spinal column, presumably
equivalent to the paravertebral BAT deposits seen in humans13
(Fig. 1a). The presence of PD-L1 within BAT was evident at the
RNA level as well (Fig. 1c). Histology of each of these deposits in
both WT and PD-L1 KO mice conﬁrmed their identity as BAT,
with no obvious morphological differences between the two
strains (Fig. 1d–h). PET imaging with full-sized antibodies fails to
reveal any of these smaller structures and produces images of far
lower resolution, while they are clearly distinguishable with our
method11. Surgical removal of the interscapular brown fat from
mice injected with radiolabeled versions of B3 and A12 followed
by scintillation counting of the isolated organ further demon-
strated speciﬁcity of the PET signal for BAT (Supplementary
Fig. 3B). While both PD-L1-speciﬁc VHHs B3 and A12 showed
comparable tissue distributions, a control VHH labeled with 64Cu
showed no accumulation of label in BAT (Supplementary
Fig. 3C).
We next examined whether PD-L1 expression was a general
property of BAT across strains, and remained present as mice age.
PD-L1 as detected by immuno-PET was present in BALB/c mice
with a distribution similar to the C57BL/6 animals (Fig. 1i). Older
animals maintained expression of PD-L1, with BAT deposits
clearly visible by anti-PD-L1 PET in 6-month-old mice, The
observed distribution is consistent with the expected decrease in
BAT mass, as observed by other methods (Fig. 1j)24, 25. While we
saw only a faint anti-PD-L1 signal in lymphoid tissue, mice
implanted with the B16 melanoma showed strong, tumor-speciﬁc
staining comparable to that seen in BAT (Fig. 1k; Supplementary
Movie 1), consistent with known positivity of B16 for PD-L1.
BAT is therefore the major site of PD-L1 expression in the naive
mouse.
We imaged C57BL/6 mice with 18F-FDG to compare
visualization of BAT with our anti-PD-L1 imaging method.
18F-FDG imaging showed fully overlapping BAT structures as
seen with anti-PD-L1 immuno-PET, although at considerably
lower resolution (Fig. 1l)26. PD-L1 immuno-PET thus represents
an advance not only in imaging low abundance immune
receptors, but also offers improved resolution for the identiﬁca-
tion of small brown fat deposits in the mouse.
PD-L1 is expressed on brown adipocytes. Given the intensity of
signal in the BAT compared to that in primary immune organs,
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we asked whether brown adipocytes themselves expressed PD-L1.
We established WT into PD-L1−/− and PD-L1−/− into WT
bone marrow (BM) chimeras and imaged them 7–8 weeks
after transplant with radiolabeled B3 to determine whether PD-L1
was expressed on non-hematopoietic cells in BAT. At this
time point, chimerism in the spleen is complete for both
lymphoid and myeloid cells (data not shown). We saw a
strong PET-CT signal in BAT from irradiated WT mice engrafted
with PD-L1 KO bone marrow, a signal absent from PD-L1 KO
recipients that received WT bone marrow (Fig. 2a). Consistent
with this ﬁnding, WT mice injected with Alexa647-labeled
B3 showed staining of BAT cells with adipocyte morphology
by confocal microscopy; such signal was absent in animals
injected with a labeled control VHH of irrelevant speciﬁcity
(Fig. 2b). These results establish that cells of hematopoietic
origin do not measurably contribute to the PD-L1 signal seen in
BAT.
We next harvested pre-adipocytes from the BAT of three-week
old WT mice27. Low levels of expression of PD-L1 and PD-1
on pre-adipocytes were evident by ﬂow cytometry (Fig. 2c).
Although PD-L1 expression appears reduced in cultured
pre-adipocytes from PD-1 KO mice, PD-L1 expression in the
mature BAT from PD-1 KO mice was maintained at
the transcript level, and could be visualized by PET/CT
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Fig. 1 PD-L1 immuno-PET reveals expression in brown adipose tissue. a, b PET-CT 3D projection images of 6-week-old C57BL/6 mice (left panel), PET-CT
axial slice through the brown adipose tissue (BAT) (top right panel) with companion CT axial image (bottom right panel). a 18F-B3 image from a WT mouse.
b 18F-B3 image from a PD-L1 knockout (KO). c PD-L1 and PD-1 transcript levels measured by RNAseq in WT BAT. d Magniﬁcation of 3D projection of
thorax from a. Arrows show BAT deposits. f–h H&E stained tissue sections 10× magniﬁcation. e, f Principal interscapular BAT deposit from WT e and PD-L1
KO f mice. g, h small parathoracic BAT deposits from WT g and PD-L1 KO h mice. i, j 18F-B3 PET-CT 3D projection image of a 6-week-old BALB/c WT
mouse i and 6-month-old C57BL/6 WT mouse j. k 18F- B3 image from a WT mouse injected with subcutaneous B16 melanoma (arrow). l 18F-FDG image
of 5-week-old C57BL/6 mouse. Images are all window-leveled to the same intensity. Three biological replicates were performed for each experiment. Error
bars indicate standard error of mean (SEM)
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Fig. 2 Non-hematopoietic cells in BAT express PD-L1. a PET-CT axial slice through BAT imaged with 64Cu-B3. (Top panels) WT (left) and PD-L1 KO (right)
mice. (Bottom panels) Bone marrow chimeras; WT bone marrow into PD-L1 KO mice (left), and PD-L1 KO bone marrow into WT mice (right). N= 3 per
chimera. b Confocal microscopy on brown fat resected from WT mice injected with Alexa647-labeled B3 or a non-speciﬁc control VHH. c Flow cytometry
using the indicated antibody on cultured pre-adipocytes isolated from WT, PD-L1 KO, and PD-1 KO BAT. d Mice were imaged by PET-CT two hours after
injection with 64Cu-B3. A 3D projection image comparing the torso and head of imaged WT, PD-L1 KO, and PD-1 KO mice is shown. e Quantiﬁcation of
background subtracted BAT signal from C57BL/6 mice analyzed as in d. Two mice were analyzed per group. f PD-L1 transcript levels measured by RNAseq
in WT and PD-1 KO BAT g QPCR for PD-L1, PD-1 and Ucp1 transcripts on in vitro differentiated brown adipocytes. X axis indicates the day of culture after
the induction differentiation. Each result is representative of at least two independent experiments. Error bars indicate SEM
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Fig. 3 PD-L1 is expressed on brown adipocytes. a QPCR for the immune genes CD11b and CD4 in the ﬂoating fraction (FF) (left panel) and stromovascular
fraction (SVF) (middle panel), and the brown fat gene UCP-1 in the FF from isolated brown fat and white fat. Y-axis shows relative expression normalized to
18S. b PD-L1 ﬂow cytometry using αPD-L1 or B3 as indicated on CD45 + populations extracted from BAT SVF or spleens of WT mice. PD-L1 is only clearly
detectable in splenic macrophages and myeloid DCs. Y axis is normalized cell counts. X axis shows MFI for each antibody or VHH as indicated in the ﬁgure
legend. c Quantiﬁcation of the data in b including B cell and T cell populations. d PD-1 ﬂow cytometry on CD45 + cells fromWT spleen and BAT SVF. e The
lipid fraction was analyzed by ﬂow cytometry and brown adipocytes were identiﬁed as CD45− large granular cells using the gating strategy shown on a
representative sample from a WT mouse stained with isotype control antibody. The great majority of the small granular counts are from free lipid derived
from ruptured adipocytes. f Flow cytometry using anti-PD-L1 or isotype control antibody on FF CD45− brown adipocytes isolated as in e compared to
CD45 + cells from the SVF. g Flow cytometry on brown adipocytes as in f isolated from FF WT and PD-L1 KO mice. Each result is representative of at least
two independent experiments with six pooled BAT samples per experiment
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(Fig. 2d–f). Analysis by quantitative PCR of in vitro differentiated
brown adipocytes showed that levels of PD-L1 and PD-1 mRNA
increase in the course of differentiation. Both genes are
thus expressed in brown adipocytes and their expression
is regulated during brown adipocyte development in vitro
(Fig. 2g).
To show that brown adipocytes themselves express PD-L1 by
an independent method, we analyzed them by ﬂow cytometry.
Isolation of brown adipocytes from BAT poses a challenge
because of their inherent fragility28. We harvested brown
adipocytes from the ﬂoating fraction (FF) of collagenase-
digested BAT. This isolated fraction contained high levels of
Ucp1 RNA when compared to ﬂoating cells isolated from
subcutaneous white adipose tissue (scWAT), and was negative for
hematopoietic markers when compared to the stromal vascular
fraction (SVF), conﬁrming the purity of mature brown adipocytes
(Fig. 3a). As predicted by imaging of the bone marrow chimeras,
ﬂow cytometry on CD45+ hematopoietic cells isolated from the
SVF showed minimal PD-L1 expression on all cell types
examined, with levels far below that of PD-L1 +myeloid DCs in
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Fig. 4 PD-L1 is an activation-independent marker of BAT. a 64Cu-B3 PET-CT 3D projection image of age and sex matched C57BL/6 mice held at room
temperature (left panel) or held at 4C (right panel) for 90min prior to injection of radiolabeled B3. Imaging was performed 60min after 64Cu-B3 injection.
b PET signal of BAT normalized to spleen from matched animals treated and imaged as in a. c Ucp-1 qPCR on RNA isolated from BAT excised from mice
included in b. d 64Cu-B3 PET-CT 3D projection image acquired as in a of age and sex matched C57BL/6 mice treated with 10 mg/kg of the β-adrenergic
agonist CL316243 given i.p. 45min before injection of radiolabeled B3 (right panel) or left untreated (left panel, naive). e PET signal of BAT normalized to
spleen and muscle from matched animals treated and imaged as in d. f Immunoblot for UCP-1 (top panel) on lystates from BAT excised from the mice
included in d with quantiﬁcation of normalized UCP-1 signal intensity (bottom panel) Numbers indicate biological replicates. g, h 18F-FDG g or 64Cu-B3
h PET-CT 3D projection image acquired on naive or CL316243-treated mice as in c. The mice in g, h are identical but treated and imaged 24 h apart
(18F-FDG followed by 64Cu-B3) to allow for 18F radiodecay. i-k Matched animals were treated and imaged as g, h and PET signal was normalized and
quanitifed. i 18F-FDG signal of BAT normalized to muscle and liver. j 64Cu-B3 signal of BAT normalized to spleen. k signal ratio of 18F-FDG to 64Cu-B3 for
each mouse represented in i, j. Error bars throughout show SEM. Statistical signiﬁcance was determined by a Student’s t-test. Three biological replicates
were performed for each condition in each experiment
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the spleen, a tissue where PD-L1 is barely detectable by immuno-
PET (Fig. 3b, c). The CD45+ cells in the SVF also showed
minimal expression of PD-1 in wild-type mice (Fig. 3d). Brown
adipocytes were gated from the FF and analyzed separately for
PD-L1 expression (Fig. 3e). As expected, the PD-L1 signal from
the brown adipocytes was considerably higher than that observed
in the CD45 + fraction (Fig. 3f), with staining altogether absent
on brown adipocytes from PD-L1 KO mice (Fig. 3g). Taken
together, these data establish the expression of PD-L1 on brown
adipocytes.
PD-L1 is an activation-independent marker of brown fat.
18F-FDG is currently the preferred method to image BAT
non-invasively and does so at low resolution when compared to
anti-PD-L1 immuno-PET. The identiﬁcation of brown fat using
18F-FDG and other metabolite-based imaging reagents (e.g.,
11C-acetate, 14(R,S)-18F-ﬂuoro-6-thia-heptadecanoic acid) is
linked to its metabolic activity, speciﬁcally the presence and
activity of the glucose transporters responsible for uptake of
18F-FDG29. Cold exposure or treatment with β-adrenoreceptor
agonists can modulate 18F-FDG uptake but cannot visualize BAT
mass per se. Imaging of total BAT volume, independent of its
metabolic activity has not been possible until now. This is a
serious limitation, when screening for metabolic interventions
considered for the treatment of obesity, type 2 diabetes and other
metabolic disorders. Anti-PD-L1 imaging enables direct detection
of brown adipocytes independent of their metabolic activity. To
verify this, we determined whether PD-L1 levels change in brown
fat in response to signals that activate BAT. We ﬁrst subjected
C57BL/6 WT mice to a cold shock at 4 °C for 1 h, followed by
imaging with 64Cu-labeled B3. Consistent with the hypothesis
that PD-L1 expression is not substantially altered by BAT acti-
vation, cold-exposed mice showed PD-L1 signals that were
identical to the signal from mice housed at room temperature (25
°C) (Fig. 4a, b, and Supplementary Fig. 4a), with a corresponding
increase in Ucp-1 mRNA (Fig. 4c); no clear change in Ucp-1
protein was detectable over the time interval examined (Supple-
mentary Fig. 4b). Whereas BAT is directly activated by signals
through the β-adrenergic receptor, exposure of animals to the
β-agonist CL-316243 led to minimal changes in PD-L1 expression
compared to naive animals (Fig. 4d, e, and Supplementary
Fig. 4c), despite a small increase in Ucp-1 (Fig. 4f). The addition
of propranolol to CL-316243-treated animals also had no
appreciable effect on PD-L1 signal intensity (Supplementary
Fig. 4d). In addition, mice treated with CL-316243 showed a clear
increase in 18F-FDG signal from BAT, while those same animals
treated 1 day later with a second dose of CL-316243 showed no
such increase in PD-L1 signal, leading to an increase in the
18F-FDG /PD-L1 signal ratio associated with β-agonist treatment
(Fig. 4g–k; Supplementary Movies 2–5). Collectively, these ﬁnd-
ings demonstrate that PD-L1 is the ﬁrst identiﬁed activation-
independent marker of BAT suitable for live animal imaging.
Discussion
The PD-1/PD-L1 axis has attracted attention in immunotherapy
of cancer, mostly because of its correlation with exhaustion of
T cells and the ability to reverse such exhaustion through appli-
cation of blocking antibodies. We now show that BAT is the
principal tissue expressing PD-L1 in the naive mouse, with signal
intensities higher than from any other tissue and comparable to
murine malignancies such as the widely used B16 melanoma. A
variety of cell types express PD-L1 at low levels. Many normal
and malignant tissues increase PD-L1 expression in response to
IFN-γ. Previous studies have speculated that PD-L1 may be
expressed on adipose tissue-associated hematopoietic cells as a
marker of immune cell inﬁltration, based largely on low-
resolution imaging and ex vivo scintillation counting. Through
a combination of biochemical and genetic approaches we show
that brown adipocytes themselves express PD-L1. Using high
resolution VHH-based anti-PD-L1 immuno-PET, we identify
even small brown adipose deposits within the mouse thorax,
independent of strain or age. PD-L1 should thus be considered a
general marker for brown fat in preclinical mouse models, where
it can be used also for longitudinal observations. In humans,
brown fat deposits are generally small, and are unlikely to be
properly visualized using traditional antibody scaffold-based
imaging, as is suggested by the comparatively poor resolution
of imaging techniques that use full-sized antibodies in the mouse.
In live animals brown fat is imaged almost exclusively by using
18F-FDG, a glucose analog that is taken up by metabolically active
cells, including brown adipocytes. However, relying on metabolic
activity as the only means of detecting brown fat has obvious
limitations, particularly when aiming for modiﬁcation of its
activity either genetically or pharmacologically. We found that
PD-L1 expression was largely independent of metabolic activity
and could be used to label BAT in naive mice as well as in animals
undergoing cold stress or treatment with β-agonists. Our results
establish the ﬁrst available method to detect and measure total
brown fat volume independent of its metabolic activity. Whether
PD-L1 is also expressed on beige adipocytes in mice is presently
unclear, but is an important area of investigation. Given the
clinical interest in PD-L1 as both a therapeutic target and a tumor
biomarker, whether this molecule is also present on beige and
brown adipocytes in humans is a question that needs answering.
The size of human brown fat stores may not allow their visuali-
zation using currently available full-sized 89Zr conjugated anti-
bodies for imaging, due to the poor resolution of antibody-based
PET. An approach similar to that described here may need to be
developed to enable visualization of human PD-L1.
In addition to their well-studied role in modulating TCR sig-
naling, clues that the PD-1/PD-L1 axis also affects metabolic
pathways are beginning to emerge30–32. B16 melanoma expresses
both PD-1 and PD-L1, with signaling through PD-1 on tumor
cells leading to enhanced tumorigenesis. When PD-1 binds to its
target ligand, T cells show repressed glycolysis and enhanced
lipolysis32, with a possible role for the T cell-speciﬁc costimula-
tory molecule CD28, although details of the signaling events that
control these effects remain to be worked out. Whether the
ﬁndings reported for T cells represent a wider role for PD-1/PD-
L1 in metabolic regulation remains unknown. Signaling proper-
ties of PD-L1 have gone mostly unexplored. Our data not only
demonstrate a clear role for PD-L1 as a marker for brown fat, but
also suggest the possibility that PD-L1 has a more general
metabolic function, potentially even regulating the activity of this
important metabolic organ.
Methods
Animals. All mice were housed at either the Dana Farber Cancer Institute or the
Whitehead Institute for Biomedical Research and were maintained according to
protocols approved by the DFCI Committee on Animal Care or the MIT Com-
mittee on Animal Care, respectively. C57BL/6 and BALB/c mice were purchased
from Jackson Labs or bred in house. PD-L1 knockout mice were a gift from Arlene
Sharpe (Harvard Medical School; Boston, MA). A three year old male alpaca
(Vicugna pacos) was purchased locally, maintained in pasture, and immunized
following a protocol authorized by the Tufts University Cummings Veterinary
School Institutional Animal Care and Use Committee (IACUC).
VHH Library generation. A male alpaca (Vicugna pacos) was immunized with a
mixture of recombinant mouse and human proteins, including mouse PD-L1. A
primary immunization was followed by four boosts, spaced two weeks apart, each
containing 200 μg of mPD-L1 mixed 1:1 in alum (Thermo Scientiﬁc). Following
immunization, total RNA was isolated from ~ 106 fresh PBLs using the RNeasy
Plus Mini Kit (Qiagen), following the manufacturer’s instructions. First strand
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cDNA synthesis was performed using SuperScript III reverse transcriptase (Life
Technologies) and a combination of oligo dT, random hexamer or
immunoglobulin-speciﬁc primers, AlCH2 and AlCH2.2, as previously described22.
PCR ampliﬁcation of VHH sequences and phage library generation followed a
previously published procedure. Following transformation into TGI cells (Agilent),
the total number of independent clones was estimated to be 3.2 × 106. Ninety-six
clones were selected at random and sequenced to assess library diversity. The
resulting phagemid libraries were stored at −80 °C.
Selection of VHHs by phage display. Two hundred microliters of the immunized
VHH phage library was inoculated in 100 ml super optimal broth (SOC) with 50
µg/ml ampicillin. The culture was grown to mid-log phase, and infected with 100 µl
1014 PFU/ml VCSM13 helper phage. The culture was then incubated for 2 h at 37 °
C, the cells collected by centrifugation, and re-suspended in 100 ml 2YT, 0.1%
glucose, 50 µg/ml kanamycin and 50 µg/ml ampicillin. Cultures were incubated
overnight at 30 °C, then centrifuged for 20 min at 7700 × g, followed by phage
precipitation from the resulting supernatant with 20% PEG-6000/500 mM NaCl at
4 °C, and resuspension in PBS.
One hundred micrograms of recombinant mouse PD-L1-Fc was biotinylated by
coupling Chromalink NHS-biotin reagent (Solulink) to primary amines for 90 min
in 100 mM phosphate buffer, pH 7.4, 150 mM NaCl. The reaction was then run
through an Amicon 10 kDa MWCO concentrator (EMD Millipore) to remove
remaining NHS-biotin. Incorporation of biotin was monitored
spectrophotometrically, following the manufacturer’s guidelines. 100 µl MyOne
Streptavidin-T1 Dynabeads (Life Technologies) were blocked in PBS plus 2% (w/v)
mouse serum in a microfuge tube for 2 h at 37 °C. Following blocking, 20 µg
biotinlyated PD-L1-Fc in mouse serum was added to the beads, and incubated for
30 min at room temperature, with agitation. The beads were then washed 3× in
PBS, and 200 µl of 1014 PFU/ml M13 phage displaying the VHH library were
added in PBS/mouse serum for 1 h at room temperature. The beads were then
washed 15× with PBS, 0.1% Tween-20. Phage was eluted by the addition of E. coli
ER2738 (NEB) for 15 min at 37 °C, followed by elution with 200 mM glycine, pH
2.2, for 10 min at room temperature. The glycine elution was neutralized and
pooled with the E. coli ER2738 culture, and plated onto 2YT agar plates
supplemented with 2% glucose, 5 µg/ml tetracycline and 10 µg/ml ampicillin, and
grown overnight at 37 °C. A second round of panning was performed with the
following modiﬁcations: 2 µg of biotinylated PD-L1-Fc was used as bait, and
incubated with 2 µl 1014 PFU/ml M13 phage displaying the ﬁrst-round VHH
library for 15 min at 37 °C, followed by extended washes in PBS with 0.1%
Tween-20.
Following two rounds of phage panning, 96 colonies were isolated in 96-well
round-bottom plates and grown to mid-log phase at 37 °C in 200 µl 2YT, 10 µg/ml
ampicillin, 5 µg/ml tetracycline, induced with 3 mM IPTG and grown overnight at
30 °C. Plates were centrifuged at 12 X kg for 10 min, and 100 µl of supernatant was
mixed with an equal volume of PBS, 5% (w/v) nonfat dry milk. This mixture was
added to an ELISA plate coated with 1 µg/ml PD-L1-Fc. Following four washes in
PBS, 1% Tween-20, anti-Etag antibody (Bethyl) was added at a 1:10,000 dilution in
PBS, 5% (w/v) nonfat dry milk for 1 h at room temperature. The plate was
developed with fast kinetic TMB (Sigma) and quenched with 1M HCl. Absorbance
at 450 nm was determined in a plate reader (Spectramax, Molecular Devices).
Cloning and expression of B3 and A12. B3 coding sequence were sub-cloned into
the E. coli periplasmic expression vector pHEN6 using the PCR primers 189 (5′-
tactcgcggcccagccGGCCCAACCGGCCATGGC-3′) and 190 (5′-agtcctcctgagga-
gacggtgaccGAGACGGTGACCTGGGTCCCC-3′) to allow for Gibson cloning and
the inclusion of a C-terminal sortase motif and 6xHis tag. WK6 E. coli containing
the plasmid were grown to mid-log phase at 37 °C in TB plus ampicillin, and
induced with 1 mM IPTG overnight at 30 °C. Cells were harvested by centrifuga-
tion at 5000 × g for 15 min at 4 °C, then resuspened in 25 ml 1x TES buffer (200
mM Tris, pH 8, 0.65 mM EDTA, 0.5 M sucrose) per liter culture, and incubated for
1 h at 4 °C with agitation. Resuspended cells wre then submitted to osmotic shock
by diluting 1:4 in 0.25× TES, and incubating overnight at 4 °C. The periplasmic
fraction was isolated by centrifugation at 8000 rpm for 30 min at 4 °C, and then
loaded onto Ni-NTA (Qiagen) in 50 mM Tris, pH 8, 150 mM NaCl and 10 mM
imidazole. Protein was eluted in 50 mM Tris, pH 8, 150 mM NaCl, 500 mM imi-
dazole and 10% glycerol, then loaded onto a Superdex 75 10/300 column in 50 mM
Tris, pH 8, 150 mM NaCl, 10% glycerol. Recombinant VHH purity was assessed by
SDS-PAGE, and peak fractions were recovered and concentrated with an Amicon
10,000 KDa MWCO ﬁltration unit (Millipore), and stored at −80 °C.
C-terminal labeling of VHHs with Biotin or Alexa647. A heptamutant variant of
S. aureus Sortase A was used to label B3 and A12 by incubating 30 uM of puriﬁed
VHH protein with 5uM 7M SrtA and 100 uM GGGK-Biotin or GGGK-Alexa647
nucleophiles in 50 mM Tris, pH 8, 150 mM NaCl for 2 h at room temperature.
Unreacted VHH and 7M SrtA were removed by adsorption onto Ni-NTA agarose
beads (Qiagen). The unbound fraction was concentrated and excess nucleophile
with an Amicon 3,000 KDa MWCO ﬁltration unit (Millipore), and stored at
−80 °C.
ELISAs. High binding plates microtiter plates (Corning) were coated with
recombinant Fc fusion proteins (S.A.) overnight at 25 ng/ml (CTLA-4, mPD-L1) or
100 ng/ml (hPD-L1) in carbonate buffer. Biotinylated VHHs or antibodies (BD
Biosciences) were incubated on the coated plates in 10% inactivated fetal calf serum
in phosphate buffered saline for 1 h in the presence or absence of unlabeled VHH
or antibody across a range of concentrations, washed in 0.5% Tween in PBS and
then developed using streptavidin-HRP (BD biosciences) and tetramethylbenzidine
(TMB). For plate-bound ligand binding assays, B7-1 and PD-1 Fc fusions (R&D
systems) were incubated with plate-bound ligands for 1 h in the presence of VHHs
or antibodies. Plates were then washed and binding was determined using bioti-
nylated polyclonal antibodies against B7-1 and PD-1 (R&D systems, 1:1000 dilu-
tion) respectively, followed by incubation with streptavidin-HRP and then
development with TMB.
Flow cytometry. Cells were analyzed using a FACS Fortessa (BD) or LSR II (BD).
All antibodies were directly conjugated and obtained from BD Pharmingen with
the exception of antibodies to mouse and human PD-L1 (BioLegend), mouse
CTLA-4 (BioLegend), mouse TIM3 (BioLegend) and mouse CD44 (Ebiosciences).
All antibodies were used at a 1:100 dilution. Staining protocols followed manu-
facturers instructions. VHHs used in ﬂow cytometry were directly conjugated to
Alexa647, diluted to 2 µg/ml in 10% IFCS in PBS and incubated with cells for 15
min on ice. Spleen populations were identiﬁed using the following markers: B cells
(CD19 + ), CD4 T cells (CD3 + CD4 + ), CD8 T cells (CD3 + CD8 + ), myeloid DCs
(CD19-CD3-CD11b + CD11c + ) according to manufacturers’ recommendations
(Supplmentary Figure 6).
Bone marrow chimera generation. Donor bone marrow was harvested from the
femurs of WT or PD-L1 KO mice. Recipients were irradiated with 600 rads at time
0 and 4 h for a total of 1200 rads. One hour later, they were injected by tail vein
with 100 μl collected bone marrow cells in PBS. Two donor animals were used for
each recipient with ~ 5 × 106 bone marrow cells used per transfusion. After
transfusion, mice were housed in autoclaved cages, and were treated with Septra
water for 2 weeks. Imaging analysis was performed 6-7 weeks after bone marrow
transfusion.
In vitro differentiation of BAT. BAT was isolated and cultured following pre-
viously described methods27. Brieﬂy, 2 to 3-week-old C57BL/6, PD-L1 KO or PD-1
mice were sacriﬁced, and interscapular BAT was collected, minced and digested
with and with collagenase digestion buffer (Hanks balanced salt solution, 0.2%
collagenase, 2% BSA). Pre-adipocytes cells were collected by sequential ﬁltering
through 70 µm and 40 µm membranes and centrifugation. Pre-adipocytes were
cultured to conﬂuence in DMEM supplemented with glutamine (Life Technolo-
gies), 5% new-born calf serum (Invitrogen), 5% fetal calf serum and pen/strep (Life
Technologies), and induced to differentiate for 5 days with DMEM containing 10%
fetal bovine serum (Life Technologies), 850 nM insulin (Sigma), 0.5 µM dex-
amethasone (Sigma), 250 µM 3-isobutyl-1-methylxanthine, phosphodiesterase
inhibitor (IBMX, Sigma), 1 µM rosiglitazone (Sigma), 1 nM T3 (Sigma).
Brown adipocyte isolation for ﬂow cytometry. Mice were euthanized and BAT
was surgically removed from the interscapular region of BL6 WT or PD-L1 KO
mice and associated WAT was removed. Tissue was minced with scissors and then
digested for 30 min at 37 C with vigorous shaking (350 rpm). After ﬁltration (150
um mesh) and dilution in room temperature DMEM, the cell mixture was cen-
trifuged (700 g) at room temperature. Mature brown adipocytes (ﬂoating fraction)
separated from the stromal vascular fraction (SVF) on top of the solution and were
carefully pipetted off using a 1 ml pipette tip with the tip cut off to allow aspiration
of larger pieces. The SVF fraction at the bottom of the tube was separately analyzed
and is the source of the CD45 + cells (this is unclear). Cells were stained for 10 min
at room temperature with either isotype control antibody or anti-PD-L1 (10
F.9G2), washed, and resuspended after centrifugation. Both fractions were analyzed
by ﬂow cytometry. Brown adipocytes were identiﬁed by size and granularity, and
by negative staining for CD45 as previously described. Cells were analyzed on an
LSRFortessa (BD Biosciences).
Quantitative PCR. Total RNA was isolated from in vitro cultured cells at different
time points of differentiation using TRizol reagent (Life Technologies/Ambion)
and a miRNeasy Mini Kit (Qiagen). Three hundred nanograms were reverse
transcribed using Superscript II reverse transcriptase (LifeTechnologies/Invitrogen)
using 300 ng random hexamers (LifeTechnologies/Invitrogen). The cDNA was
diluted 1:10 and 2.5 µl for a 96-well plate or 1 µl for a 384 well plate were used for
quantitative Real-time PCR. qPCR was carried out on an ABI7900HT Fast real-
time PCR system (Applied Biosystems) and analyzed using the delta delta Ct
method normalized to 18S. The following primer sets were used: 18S fwd 5′-
GTAACCCGTTGAACCCCATT-3′; 18S rev 5′-CCATCCAATCGGTAGTAGC-3′;
Ucp1 fwd 5′-ACTGCCACACCTCCAGTCATT-3′;
Ucp1 rev 5′-CTTTGCCTCACTCAGGATTGG-3′; Pd-l1 fwd 5′-
TGCTGCATAATCAGCTACGG-3′; Pd-l1 rev 5′-
CCACGGAAATTCTCTGGTTG-3′.
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Fluorescence microscopy. Adult WT mice were injected IP with 50 ug of B3-
Alexa647 or 96G3m-Alexa647 (control VHH). Mice were sacriﬁced one hour after
injection and interscapular BAT was collected, mounted on a coverslip and imaged
with a Zeiss AxioPlan 2 microscope. Images were analyzed using Metamorph and
ImageJ software.
Imaging. To label puriﬁed VHH with tetrazine, reactions were performed in 50
mM Tris·HCl, pH 7.5 supplemented with 10 mM CaCl2, 150 mM NaCl, 500uM
triglycine-containing probe, 100 μM VHH and 5 μM sortase. After incubation at 4 °
C with agitation for 2 h, reaction products were analyzed by LC-MS, with yields
generally > 90%. Ni-NTA beads were added to the reaction mixture with agitation
for 5 min at 25 °C, followed by centrifugation to remove sortase and any remaining
unreacted His-tagged substrate. The ﬁnal product was puriﬁed by size-exclusion
chromatography in PBS. VHH-Tz (40 μl, 150 μM), PBS (300 μl), and 18F-TCO in
DMSO (4.0 mCi (148.0 MBq), 100 μl) were mixed in a microfuge tube. The tube
was sealed and shaken at room temperature for 20 min. The mixture was analyzed
by radio-TLC (instant thin layer chromatography (ITLC), 100% MeCN, Rf 18F-
TCO= 0.9, Rf 18F-VHH = 0.0) showing 90% conversion to 18F-VHH. The reac-
tion mixture was loaded onto a PD-10 size-exclusion cartridge (GE Healthcare),
and eluted with PBS. Imaging was performed on a Siemens Inveon PET/CT
imager. All PET/CT imaging procedures were approved by the Massachusetts
General Hospital subcommittee on research animal care.
Murine PD-L1 antigen production in HEK 293 cells. Coding sequences were
cloned into a modiﬁed version of the Daedalus lentiviral transfer vector, which
supported ligation independent cloning and expressed targets as a fusion with a
variant of mIgG2a. Lentivirus production was essentially as described. Transduc-
tion of HEK-293F cells (Gibco) was carried out at a scale of 30 ml in Freestyle 293
Expression media (Gibco) and cultures were expanded to a 3 l production scale.
Supernatant from 3 l culture was harvested by centrifugation (2000 × g, 10 min), 15
ml 1M MES pH 6.5 and AEBSF (ﬁnal concentration 20 µM) was added, and the
supernatant swirled at 4˚C for 1 h with a 30 ml bed volume (bv) of His60 Ni-IDA
resin (Clontech). Resin was poured into a gravity column, washed with 10 bv wash
buffer (25 mM MES, pH 6.5, 150 mM NaCl, 10% glycerol, 50 mM Arginine-Cl and
5 mM imidazole)) and eluted with 5bv elution buffer (wash buffer with 100 mM
Arginine-Cl and 0.5 M imidazole). Protein was concentrated using centrifugal units
(Amicon Ultracel-10, Millipore), and applied to a gel ﬁltration column (Sephacryl
S200 26/60, GE lifesciences) equilibrated in 25 mM MES, pH 6.5, 150 mM NaCl,
10% glycerol, 100 mM Arg-Cl. Peak fractions were collected and concentrated by as
above.
Murine PD-L1 site-speciﬁc mutagenesis. Murine PD-L1 was cloned into the SacI
and BamHI sites of the Clontech N1 mCherry-fusion vector replacing the native
leader peptide sequence with that of erythropoietin (EPO). Site-speciﬁc muta-
genesis was performed using KOD polymerase, 2 mM dNTPs and 4 mM MgCl2.
Solvent accessible positions for mutagenesis were selected based on the crystal
structure of the complex formed by human PD-L1 and PD-1 (PDB: 3BIK) and
determining the equivalent positions in mouse PD-L1 using Custal2 sequence
alignment. Each chosen position was mutated to an Ala, Glu or Arg residue with an
overall success rate of ~ 70%. All sequence-validated mutants were tested by
transient expression in suspension HEK 293 cells prior to use in the nanobody
epitope mapping experiments.
B3 epitope mapping. Wild-type and mutant PD-L1 mCherry-fusion constructs
were transiently transfected into HEK 293 S cells plated in 24-well tissue culture
plates using 1 ml of Freestyle media (Invitrogen) and PEI transfection. Three days
post transfection, 12 wells were selected at random and counted, and the average
count used to dilute cells to ~ 1 × 106 cells/ml in PBS. The Alexa 488-labeled α-PD-
L1 VHH was diluted to 0.01 μg/μl in 1X PBS and 0.2% BSA. Binding reactions were
setup in 96-well V-bottom plates using 150 μl cells (150,000) and 50 μl of diluted
nanobody. Reactions were covered in foil and incubated at room temperature with
shaking at 900 rpm in a 96-well plate shaker for 1 h. After incubation, plates were
centrifuged at 500 × g for 5 min, the supernantant removed and 200 μl of 1× PBS
and 0.2% BSA was added to wash. After two additional washes, cells were resus-
pended in 100 μl and analyzed using an Hypercyte autosampler (Intellicyt) con-
nected to a custom Blue-Yellow laser BD Accuri ﬂow cytometer. Counts were
normalized to wild type.
Statistics. Two sample comparisons used the t-test with pooled variance if there
was no evidence of inhomogeneity of variances between groups. If the variances
were unequal, the exact Wilcoxon rank sum test, a non-parametric alternative to
the t-test, was used. Every effort was made to keep testing consistent across related
experiments. For comparisons of more than two groups, analysis of variance
(ANOVA) was used if there was no evidence of inhomogeneity of variance; the
Kruskal-Wallis test was the non-parametric alternative. Tumor growth studies were
analyzed using mixed model ANOVA. Sample size was determined based on a
review of similar experiments in the literature or based on prior experience in the
lab. Animals were all randomized to treatment groups and the start of the
experiment. The experiments were not blinded unless stated in the methods.
Data availability. The data sets generated and analyzed during current study are
available from the corresponding author on reasonable request.
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